Cargando…

Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma

Detalles Bibliográficos
Autores principales:	Kagdi, Huseini, Fields, Paul, Hodson, Andrew, Taylor, Graham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044561/ http://dx.doi.org/10.1186/1742-4690-11-S1-P8

Ejemplares similares

Molecular characterization of heterogeneity in adult T-cell leukaemia/lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2015)

Molecular characterization of heterogeneity in adult T-cell leukaemia/lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2015)

The potential of CD127 as a prognostic and residual disease marker in chronic adult T cell leukaemia/lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2014)

The potential of CD127 as a prognostic and residual disease marker in chronic adult T cell leukaemia/lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2014)

CD25+CCR4+ cells as a marker of HTLV-1-infected cells in peripheral blood
por: Kagdi, Huseini, et al.
Publicado: (2014)

CD8 malignant proliferation in association with human T cell lymphotropic Virus 1 infection: a case report
por: Kagdi, Huseini, et al.
Publicado: (2015)

Risk stratification of adult T‐cell leukemia/lymphoma using immunophenotyping
por: Kagdi, Huseini H., et al.
Publicado: (2016)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

Neurolymphomatosis in patient with Adult T-cell leukaemia/lymphoma (ATLL)
por: Yoshimitsu, Maki, et al.
Publicado: (2015)

The Effect of Monthly Anti-CD25(+) Treatment with Basiliximab on the Progression of Chronic Renal Dysfunction after Lung Transplantation
por: Ross, D. J., et al.
Publicado: (2020)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma
por: Ratner, Lee, et al.
Publicado: (2015)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Burkitt's lymphoma: differential killing of Epstein-Barr virus (EBV) (+) and EBV(-) Burkitt lymphoma cells in vitro and dose-dependent lytic induction by bortezomib in vivo
por: Dufresne, AL, et al.
Publicado: (2009)

Adult T-cell leukemia/lymphoma following elevation of serum levels of soluble cytokine receptors, sCD25 and sCD30
por: Takemoto, Shigeki, et al.
Publicado: (2014)

Bortezomib enhances anti-tumor T cell immunity by remodeling Notch system
por: Thounaojam, Menaka, et al.
Publicado: (2014)

Effect of HIV infection on the expression and the activity of the proteasome in primary CD4 T cells
por: Boucau, J, et al.
Publicado: (2012)

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
por: Li, Shi-Jun, et al.
Publicado: (2020)

New targeted therapies in myelodysplastic syndrome: the role of farnesyltransferase and proteasome inhibitors
por: Gonçalves, A Cristina, et al.
Publicado: (2010)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
por: Niewerth, Denise, et al.
Publicado: (2016)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T- lymphotropic virus type 1 infection
por: Kagdi, Huseini, et al.
Publicado: (2018)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
por: Sin, Chun-fung, et al.
Publicado: (2021)

Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates
por: Kim, Ha Eun, et al.
Publicado: (2021)

P1292: BASILIXIMAB MAY BE THE POTENTIAL SOLUTION FOR SEVERE LIVER CHRONIC GRAFT-VERSUS-HOST DISEASE: A PROSPECTIVE PILOT STUDY
por: Deng, Dao-Xing, et al.
Publicado: (2023)

P351: PROTEASOME INHIBITORS INDUCE DNA DAMAGE AND MITOTIC CATASTROPHE IN ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) VIA AUTOPHAGY-MEDIATED DEGRADATION OF WEE1
por: Fung Sin, Chun, et al.
Publicado: (2023)

A role for IL-7 in regulating CD4(+)CD25(high )regulatory T cells
por: Lawson, CA, et al.
Publicado: (2005)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo
por: Huang, Hongbiao, et al.
Publicado: (2012)

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)
por: Phillips, Adrienne, et al.
Publicado: (2015)

Quantitative and qualitative analysis of CD4(+)CD25(+ )regulatory T cells in systemic lupus erythematosus patients
por: Bonelli, M, et al.
Publicado: (2005)

Bortezomib sensitizes human glioblastoma stem cells to adoptive natural killer cell cytotoxicity
por: Grossenbacher, Steven, et al.
Publicado: (2015)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_56a2dubd5v680eitft3vdgjkk0